X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Cancer Management and Research

期刊標題檢索 CANCER MANAG RE 最新評論: Review speed: 6.0 | Submission acceptance rate: 95.0 Emphasized rese... (2024-06-21)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Cancer Management and Research]您好,您是該頁面的第 149109 位訪客。

期刊簡介
期刊名稱Cancer Management and Research Cancer Management and Research
LetPub Score
6.3
51 ratings
Rate

Reputation
6.9

Influence
5.0

Speed
9.3

期刊簡稱CANCER MANAG RES
ISSN1179-1322
h-index32
CiteScore
CiteScoreSJRSNIPCiteScore Rank
7.400.6750.668
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Oncology
Q191 / 404

自引率 (2023-2024)0.00%自引率趨勢
掲載範囲
Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Specific topics covered in the journal include:

◦Epidemiology, detection and screening
◦Cellular research and biomarkers
◦Identification of biotargets and agents with novel mechanisms of action
◦Optimal clinical use of existing anticancer agents, including combination therapies
◦Radiation and surgery
◦Palliative care
◦Patient adherence, quality of life, satisfaction

The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.
官方網站https://www.dovepress.com/cancer-management-and-research-journal
在線稿件提交https://www.dovepress.com/submit_step_1.php
開放訪問Yes
出版商Dove Medical Press Ltd.
主題領域Medicine
出版國/地區UNITED STATES
發行頻率
創刊年0
每年文章數111每年文章數趨勢
黃金OA百分比96.28%
OA Related Info
APC: Yes( USD2990; )
APC waiver:Check Notes
Other charges: No
Keywords: epidemiology、cancer、anticancer agents、cancer screening、palliative care
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q3

CategoryEditionJIF QuartileJIF RankingJIF Percentage
ONCOLOGYSCIEQ3183/322
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1179-1322%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: 16 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Cancer Management and Research】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    Nature CancerH-index: 0

    CiteScore: 31.10
    JAMA OncologyH-index: 41

    CiteScore: 37.50
    JAMA OncologyH-index: 61

    CiteScore: 37.50
    Trends in CancerH-index: 0

    CiteScore: 28.50
    Liver CancerH-index: 25

    CiteScore: 20.80
    Experimental Hematology & OncologyH-index: 0

    CiteScore: 12.60
    ESMO OpenH-index: 0

    CiteScore: 11.70
    Cancer Biology & MedicineH-index: 29

    CiteScore: 9.80
    Annual Review of Cancer BiologyH-index: 0

    CiteScore: 14.50
    CancersH-index: 53

    CiteScore: 8.00
    學科內最受檢索的期刊 頁面查看次數
    Cancers209508
    OncoTargets and Therapy183294
    Journal of Oncology88245
    Cancer Biology & Medicine58478
    Molecular Therapy-Oncolytics43576
    JAMA Oncology36961
    Liver Cancer34135
    Nature Cancer33325
    Translational Lung Cancer Research29416
    JAMA Oncology28794
  •  

    Cancer Management and Research Cancer Management and Research
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    3    4    5    6    7    下一頁    末頁  (頁
/43)
  [Cancer Management and Research] 的評論撰寫評論
作者: 是志丹吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-06-21 17:53:45 評論於
Review speed: 6.0 | Submission acceptance rate: 95.0
Emphasized research directions: Oncology; Chronic disease management; Sharing of oncology rehabilitation experiences: Impact factor for 2023 is 2.5 points.
(0) 讚! | 是志丹吖

作者: 星熊东付


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-29 19:17:24 評論於
It's really slow, keep asking for the raw data
(0) 讚! | 星熊东付

作者: 北海雅蓉


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-24 16:35:56 評論於
Received
(0) 讚! | 北海雅蓉

作者: 一只素芬呀


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-09 18:23:06 評論於
It is not convenient to contact co-authors, you often have to send emails to each author and need each author to confirm. Also, it has been 3 weeks since the initial review, finding reviewers is also very slow. When submitting to another journal, ONCOtarget and therapy, after a month and a half, we couldn't find reviewers and had to withdraw the submission
(0) 讚! | 一只素芬呀

作者: 雾水旭炎


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-12 21:54:04 評論於
The period is just two or three months
(0) 讚! | 雾水旭炎

作者: 不灭幻菱


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-11 18:32:12 評論於
So excellent!
(0) 讚! | 不灭幻菱

作者: 北海雅蓉


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-02-27 08:47:57 評論於
4A in rework
(0) 讚! | 北海雅蓉

作者: Rebecca II


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-02-19 14:44:27 評論於
What is your current status now?
(0) 讚! | Rebecca II

作者: 北海雅蓉


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-22 19:25:52 評論於
1.22 or 2b..., is still only one reviewer, this is too slow, despair
(0) 讚! | 北海雅蓉

作者: 穿心妙凡


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-21 23:12:44 評論於
How valuable, currently 1A 3 weeks ?
(0) 讚! | 穿心妙凡

作者: 凌霄芮波


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-05 19:17:53 評論於
Please translate the following paragraph into English and Japanese, and title them as ":" and ":" respectively:

求v
(0) 讚! | 凌霄芮波

作者: 穿心浩思


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-05 11:15:52 評論於
Please translate the following paragraph into English and Japanese and label them as ":" and ":"
(0) 讚! | 穿心浩思

作者: 北海雅蓉


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-25 16:30:41 評論於
Please translate the following paragraph into English and Japanese, and title them ": " and ": " respectively:

12.19 2b
(0) 讚! | 北海雅蓉

作者: 梅花清安


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-25 15:27:45 評論於
Review speed: 3.0 | Submission acceptance rate: 95.0
Emphasis on research direction: Oncology 
Experience sharing: This journal has a fast acceptance process. Feel free to connect with me if needed
(0) 讚! | 梅花清安

作者: 北海雅蓉


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-11 17:47:17 評論於
I think we can send a reminder email once a month
(0) 讚! | 北海雅蓉

作者: 北海雅蓉


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-11 15:18:32 評論於
Has it been so long since you invited the reviewers? How long has your 1f been maintained? Mine has just started 1f... I can't wait to graduate
(0) 讚! | 北海雅蓉

作者: 北海雅蓉


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-06 14:01:27 評論於
Recording: Submitted on 23.11.27 1A; 11.30 1ab; 12.02 1e; 12.06 Received email explaining animal ethics issues and uploaded ethics approval; 12.08 1f; 12.11 changed back to 1e, received email requesting original WB image; 12.12 1f; 12.13 2a
(0) 讚! | 北海雅蓉

作者: 书生小柳


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-06 09:08:49 評論於
My 2a has been almost a month, and I haven't received any invitations for reviewers yet. Can I ask for a reminder?
(0) 讚! | 书生小柳

作者: 无冬海雪


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-11-06 17:10:40 評論於
Have you submitted it for review?
(0) 讚! | 无冬海雪

作者: 无冬海雪


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-11-05 19:38:17 評論於
How many more days until graduation? I can't wait
(0) 讚! | 无冬海雪

作者: 千叶超级甜


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-27 23:20:23 評論於
It has been 11 days since 1a. How are you now?
(0) 讚! | 千叶超级甜

作者: 回风嘉蕊


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-05 09:31:01 評論於
Still no news after 16 days of the 1A?
(0) 讚! | 回风嘉蕊

作者: 和风桑


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-23 11:01:02 評論於
Ethical approval is in Chinese in the hospital document, can you upload it?
(0) 讚! | 和风桑

作者: 深渊绮晴


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-14 12:52:51 評論於
We are ready to improve the quality
(0) 讚! | 深渊绮晴

作者: 经纶小哥哥


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-08 08:23:08 評論於
The official rejection rate in 2022 is 68%
(0) 讚! | 经纶小哥哥

首頁    上一頁    1    2    3    4    5    6    7    下一頁    末頁  (頁
/43)

開始撰寫 [Cancer Management and Research] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*